Ad
related to: beta thalassemia treatment options in ohio map location- Management
Find the latest thalassemia
management guidelines.
- Emerging NTD Data
See how hemoglobin levels
affect NTD patients.
- For Patients
Visit this website if you are a
patient seeking information.
- Resources
Explore resources for HCPs.
See study results & more.
- Management
Search results
Results from the WOW.Com Content Network
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [1] [5] [2] It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015.
The treatment was approved in the United Kingdom for the treatment of transfusion-dependent beta thalassemia in November 2023 [38] [39] [40] and in the United States in January 2024. [ 41 ] [ 42 ] [ 43 ]
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. [5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [8]
The groundbreaking treatment can now also be used to treat transfusion-dependent beta thalassemia in people 12 and older. Like sickle cell, beta thalassemia is an inherited blood disorder.
Patients with beta thalassemia minor are usually asymptomatic and are often monitored without treatment. [8] Beta thalassemia minor may coexist with other conditions such as chronic hepatitis B, chronic hepatitis C, non-alcoholic fatty liver disease and alcoholic liver disease that, when combined or co-existing, may cause a person to have iron ...
There are two approved forms of gene therapy for beta thalassemia. [96] [97] Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia which adds a healthy beta-globin gene to the HSCs. [98] It was approved for medical use in the United States in August 2022.
The $100-million, 55,000-square-foot center is the first treatment facility in central Ohio to offer this type of radiation therapy.
The treatment was approved in the United Kingdom for the treatment of sickle cell disease and transfusion-dependent beta thalassemia in November 2023. [10] [11] [12] It was approved in the United States for the treatment of sickle cell disease in December 2023 and for the treatment of transfusion-dependent beta thalassemia in January 2024. [13 ...
Ad
related to: beta thalassemia treatment options in ohio map location